MX2020005830A - Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos. - Google Patents

Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.

Info

Publication number
MX2020005830A
MX2020005830A MX2020005830A MX2020005830A MX2020005830A MX 2020005830 A MX2020005830 A MX 2020005830A MX 2020005830 A MX2020005830 A MX 2020005830A MX 2020005830 A MX2020005830 A MX 2020005830A MX 2020005830 A MX2020005830 A MX 2020005830A
Authority
MX
Mexico
Prior art keywords
human
human animals
light chain
antibodies
animals
Prior art date
Application number
MX2020005830A
Other languages
English (en)
Inventor
John Mcwhirter
Andrew J Murphy
Chunguang Guo
Lynn Macdonald
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020005830A publication Critical patent/MX2020005830A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan animales no humanos (y/o células no humanas) y métodos para usarlos, dichos animales no humanos (y/o células no humanas) tienen un genoma que comprende secuencias que codifican anticuerpos humanos (es decir, genes de inmunoglobulina). Los animales no humanos descritos en la presente expresan anticuerpos que contienen cadenas ligeras de inmunoglobulina (Ig) caracterizadas por la presencia de dominios V? humanos. Los animales no humanos proporcionados en la presente se caracterizan, en algunas modalidades, por la expresión de anticuerpos que contienen cadenas ligeras de V? humanas que son codificadas por secuencias codificantes de cadenas ligeras de Ig? humanas insertadas en un locus de cadena ligera de Ig? endógena de dichos animales no humanos. También se proporcionan métodos para producir anticuerpos a partir de animales no humanos, cuyos anticuerpos contienen regiones variables humanas y regiones constantes de ratón.
MX2020005830A 2017-12-05 2018-12-04 Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos. MX2020005830A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762594944P 2017-12-05 2017-12-05
US201762594946P 2017-12-05 2017-12-05
US201762609241P 2017-12-21 2017-12-21
US201762609251P 2017-12-21 2017-12-21
PCT/US2018/063841 WO2019113065A1 (en) 2017-12-05 2018-12-04 Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof

Publications (1)

Publication Number Publication Date
MX2020005830A true MX2020005830A (es) 2020-08-20

Family

ID=64734263

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020005830A MX2020005830A (es) 2017-12-05 2018-12-04 Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.
MX2024004496A MX2024004496A (es) 2017-12-05 2020-07-13 Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024004496A MX2024004496A (es) 2017-12-05 2020-07-13 Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.

Country Status (24)

Country Link
US (4) US11051498B2 (es)
EP (3) EP4140297B1 (es)
JP (3) JP7430636B2 (es)
KR (2) KR20250022220A (es)
CN (2) CN116058333A (es)
AU (2) AU2018381316B2 (es)
BR (1) BR112020011184A2 (es)
CA (1) CA3084049A1 (es)
DK (2) DK3720279T3 (es)
ES (2) ES2928995T3 (es)
FI (1) FI4140297T3 (es)
HR (2) HRP20221459T1 (es)
HU (2) HUE060608T2 (es)
IL (2) IL274797B2 (es)
LT (2) LT3720279T (es)
MX (2) MX2020005830A (es)
PL (2) PL3720279T3 (es)
PT (2) PT4140297T (es)
RS (2) RS63772B1 (es)
SG (1) SG11202003044SA (es)
SI (2) SI3720279T1 (es)
SM (2) SMT202500277T1 (es)
TW (2) TW202438676A (es)
WO (1) WO2019113065A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CA2900824A1 (en) 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
TW202438676A (zh) 2017-12-05 2024-10-01 美商再生元醫藥公司 具有經改造免疫球蛋白λ輕鏈的非人類動物及其用途
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
SG11202107589PA (en) 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
WO2021003149A1 (en) * 2019-07-01 2021-01-07 Trianni, Inc. Transgenic mammals and methods of use
FI3993623T3 (fi) * 2019-07-01 2025-05-25 Zoetis Services Llc Muuntogeeniset jyrsijät ja niiden käyttömenetelmät
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
KR20230124594A (ko) 2020-12-23 2023-08-25 리제너론 파마슈티칼스 인코포레이티드 막관통 단백질 및 이를 생산하는 세포에 결합하는 항체를 수득하는 방법
US20240317849A1 (en) 2020-12-23 2024-09-26 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CN114763558B (zh) * 2021-01-14 2024-02-20 上海泰槿生物技术有限公司 重组基因组、非人哺乳动物细胞及其产生方法和用途
US12376573B2 (en) * 2021-03-31 2025-08-05 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire
CN121065267A (zh) * 2024-06-04 2025-12-05 赛业（苏州）生物科技有限公司 用于制备四元固定轻链的基因修饰的啮齿动物及其制备方法
EP4671705A1 (de) 2024-06-25 2025-12-31 Harro Höfliger Verpackungsmaschinen GmbH Vorrichtung und verfahren zum prüfen des sprühstrahls einer baugruppe für sprühapplikatoren
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
US20260123608A1 (en) 2024-08-06 2026-05-07 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
ATE549918T1 (de) * 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
EP1311530A4 (en) * 2000-08-03 2004-10-06 Wim-Van Schooten PRODUCTION OF HUMANIZED ANTIBODIES IN TRANSGENIC ANIMALS
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP3698626A1 (en) 2001-11-30 2020-08-26 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
AU2008297070A1 (en) * 2007-09-12 2009-03-19 Probiodrug Ag Transgenic mice
RU2731084C2 (ru) * 2008-06-27 2020-08-28 Мерюс Н.В. Продуцирующие антитела млекопитающие, не являющиеся человеком
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US9445581B2 (en) * 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
SI2480675T1 (sl) * 2010-06-22 2016-08-31 Regeneron Pharmaceuticals, Inc. Miši, ki izražajo lahko verigo s spremenljivo regijo humanega lambda in konstantno mišjo regijo
LT2738259T (lt) 2011-02-25 2020-03-10 Regeneron Pharmaceuticals, Inc. Adam6 pelės
KR20140082824A (ko) 2011-10-17 2014-07-02 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
PT3527070T (pt) * 2011-12-20 2025-12-19 Regeneron Pharma Murganhos de cadeia leve humanizada
NZ810648A (en) 2012-02-01 2025-11-28 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
EP3912464A1 (en) * 2012-06-12 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
US20140235933A1 (en) 2013-02-20 2014-08-21 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
DK2986729T3 (en) 2013-04-16 2018-10-29 Regeneron Pharma TARGETED MODIFICATION OF ROOT THROUGH
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
RS60366B1 (sr) 2014-06-23 2020-07-31 Regeneron Pharma Sastavljanje dnk posredovano nukleazom
CA2968440A1 (en) 2014-11-21 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
BR112017013104A2 (en) 2014-12-19 2018-05-15 Regeneron Pharmaceuticals, Inc. methods for modifying a target genomic locus in a cell, for enhancing homologous recombination at a target genomic locus in a cell, and for producing an f0 generation from a nonhuman animal.
KR102483193B1 (ko) 2016-06-03 2023-01-04 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
TW202438676A (zh) 2017-12-05 2024-10-01 美商再生元醫藥公司 具有經改造免疫球蛋白λ輕鏈的非人類動物及其用途

Also Published As

Publication number Publication date
AU2018381316A1 (en) 2020-04-23
HUE071852T2 (hu) 2025-09-28
SI4140297T1 (sl) 2025-08-29
EP3720279B1 (en) 2022-09-21
JP2026016575A (ja) 2026-02-03
TWI827567B (zh) 2024-01-01
DK3720279T3 (da) 2022-10-24
IL274797B2 (en) 2025-06-01
RU2020118699A (ru) 2022-01-10
SMT202500277T1 (it) 2025-09-12
JP2021505141A (ja) 2021-02-18
JP7430636B2 (ja) 2024-02-13
HUE060608T2 (hu) 2023-03-28
EP4140297B1 (en) 2025-05-21
TW201938019A (zh) 2019-10-01
RS63772B1 (sr) 2022-12-30
US20190223418A1 (en) 2019-07-25
IL318197A (en) 2025-03-01
EP4596688A3 (en) 2025-11-12
PT3720279T (pt) 2022-10-06
US12356967B2 (en) 2025-07-15
US11051498B2 (en) 2021-07-06
KR20250022220A (ko) 2025-02-14
US20210345591A1 (en) 2021-11-11
PL4140297T3 (pl) 2025-08-25
KR20200093570A (ko) 2020-08-05
SI3720279T1 (sl) 2022-11-30
SMT202200448T1 (it) 2023-01-13
MX2024004496A (es) 2024-05-08
CA3084049A1 (en) 2019-06-13
IL274797B1 (en) 2025-02-01
WO2019113065A1 (en) 2019-06-13
TW202438676A (zh) 2024-10-01
CN111432635B (zh) 2022-10-21
SG11202003044SA (en) 2020-04-29
AU2018381316B2 (en) 2025-06-26
AU2025204547A1 (en) 2025-07-10
HRP20221459T1 (hr) 2023-01-20
ES2928995T3 (es) 2022-11-24
PT4140297T (pt) 2025-07-09
JP7765514B2 (ja) 2025-11-06
ES3035461T3 (en) 2025-09-03
CN116058333A (zh) 2023-05-05
EP3720279A1 (en) 2020-10-14
RU2020118699A3 (es) 2022-04-07
DK4140297T3 (da) 2025-06-23
RS67058B1 (sr) 2025-08-29
KR102760506B1 (ko) 2025-02-04
US20260020545A1 (en) 2026-01-22
EP4140297A1 (en) 2023-03-01
HRP20250920T1 (hr) 2025-09-26
PL3720279T3 (pl) 2023-01-16
CN111432635A (zh) 2020-07-17
LT3720279T (lt) 2022-10-25
LT4140297T (lt) 2025-07-25
IL274797A (en) 2020-07-30
US20210292439A1 (en) 2021-09-23
FI4140297T3 (fi) 2025-07-10
JP2024036440A (ja) 2024-03-15
EP4596688A2 (en) 2025-08-06
BR112020011184A2 (pt) 2020-11-17

Similar Documents

Publication Publication Date Title
MX2021010556A (es) Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
EP4596688A3 (en) Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
CY1122036T1 (el) Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα
NZ629639A (en) Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
MX379533B (es) Ratones de cadena ligera universal humanizados.
NZ793447A (en) Humanized rodents that express heavy chains containing vl domains
MX2023001726A (es) Anticuerpos anti-c5 y usos de los mismos.
CY1121798T1 (el) Αντισωματα ελαφριων αλυσιδων τροποποιημενων με ιστιδινη και γενετικα τροποποιημενα ζωα πλην του ανθρωπου για τη δημιουργια αυτων
CY1123046T1 (el) Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ
MY178882A (en) Non-human animals with modified immunoglobulin heavy chain sequences
IN2014DN08163A (es)
MX2015012540A (es) Ratón de cadena ligera común.
MX2016009050A (es) Construcciones biespecificas de union a los antigenos cd3 y cd19.
MX2021014818A (es) Anticuerpos monoclonales anti-cd303.
WO2010076400A8 (fr) Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome intraoculaire primitif
MX2024009271A (es) Constructos de anticuerpos de acidos nucleicos optimizados.
MX2018008701A (es) Roedores que tienen una region de diversidad de cadena pesada modificada geneticamente.
EP4249502A3 (en) Rodents expressing humanized c1q complex